Thyroid Carcinoma Clinical Trial
Official title:
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
The objective of this study is to determine the feasibility of pazopanib treatment interruption with reintroduction at progression in iodine refractory progressive Differentiated Thyroid Cancer (DTC) patients as compared to pazopanib continuous administration.
Total or near-total thyroidectomy is the primary treatment for differentiated thyroid
carcinoma. Postoperatively, DTC are treated with radioiodine (131I) and thyroid stimulating
hormone (TSH) suppressive levothyroxine therapy.
But 5% to 20% of patients with DTC develop distant metastases; some of them become refractory
to 131I therapy.
Targeted therapies have been studied in iodine refractory DTC for several years but none of
these treatments has yet been approved in DTC and clinicians continue to enroll patients in
clinical trials. The agents used so far in thyroid cancer are small molecules sharing the
property to inhibit various tyrosine kinase receptors such as Vascular Endothelial Growth
Factor Receptor (VEGFR), Epidermal Growth Factor Receptor (EGFR), RET or c-met.
The VEGF (Vascular Endothelial Growth Factor) is one of the several pro angiogenic molecules
that play a pivotal role in angiogenesis, one of the mechanisms involved in tumor growth and
dissemination.
VEGF expression is highly prevalent in Papillary Thyroid Carcinoma (PTCs) (79%), Follicular
Thyroid Carcinoma (FTCs) (50%) or Poorly Differentiated Thyroid Carcinoma (PDTCs) (37%) and
VEGFR is respectively expressed in 76%, 83% and 25% for VEGRF-1 and 68%, 56% and 37% for
VEGRF-2.
Pazopanib (GW786034 - GlaxoSmithKline) is an orally administered, potent multitarget tyrosine
kinase inhibitor of VEGFR in particular (but also of PDGFR-α and -β, and stem cell factor
receptor c-Kit).
The results obtained in metastatic or locally advanced refractory DTC are currently available
(phase II study of 39 patients with metastatic, rapidly progressive RAI-refractory DTC,
treated with pazopanib 800mg daily, were published in Lancet Oncology in 2010 by KC Bible),
demonstrating the efficacy of these therapies in this indication. However, no clear data is
yet available indicating the optimal duration of treatment in first line therapy: patients
are currently treated until progression or until drug discontinuation due to toxicity.
Indeed, patients may have some difficulties to manage the chronic mild to moderate (grade
1-2) side-effects related to long-term treatment, leading some asymptomatic patients in whom
tumor is controlled by TKI treatment to ask for treatment interruption.
The intermittent administration should avoid the occurrence of long-term adverse event and
subsequent dose reductions or discontinuation, thus allowing a longer control of underlying
disease.
All these considerations led our reflexion in the design of the present study, that is to say
to determine the feasibility of pazopanib treatment interruption with reintroduction at
progression in iodine refractory progressive DTC patients as compared to pazopanib continuous
administration, after 6 initial cycles of pazopanib 800 mg daily for all patients included in
the study, with a strong rationale for intermittent administration of pazopanib.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Withdrawn |
NCT01707056 -
The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma
|
N/A | |
Completed |
NCT00215605 -
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
Terminated |
NCT04327999 -
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
|
Phase 2 | |
Completed |
NCT02194920 -
Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function
|
N/A | |
Enrolling by invitation |
NCT06095362 -
Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW
|
Phase 1 | |
Not yet recruiting |
NCT05949424 -
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
|
Phase 4 | |
Active, not recruiting |
NCT02145143 -
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
|
N/A | |
Terminated |
NCT01865838 -
A Study Into the Effect of Seprafilm in Open Total Thyroidectomy
|
N/A | |
Recruiting |
NCT00749697 -
Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
|
N/A | |
Enrolling by invitation |
NCT04411290 -
Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
|
||
Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
Active, not recruiting |
NCT02185560 -
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
|
||
Completed |
NCT04462471 -
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
|
Phase 1 | |
Completed |
NCT01433809 -
Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm
|
N/A | |
Recruiting |
NCT00929318 -
Influence of Thyroid Hormones on the Woundhealing Process
|
N/A | |
Completed |
NCT05178186 -
Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer
|
N/A | |
Completed |
NCT02773667 -
Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
|
||
Not yet recruiting |
NCT00993837 -
Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma
|
N/A |